Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Allogene Therapeutics (ALLO) Accumulated Depreciation & Amortization (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Accumulated Depreciation & Amortization for 7 consecutive years, with $12.4 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization fell 8.82% to $12.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.4 million through Dec 2025, down 8.82% year-over-year, with the annual reading at $12.4 million for FY2025, 8.82% down from the prior year.
  • Accumulated Depreciation & Amortization hit $12.4 million in Q4 2025 for Allogene Therapeutics, up from $9.3 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $40.4 million in Q1 2023 to a low of $3.1 million in Q1 2025.
  • Historically, Accumulated Depreciation & Amortization has averaged $15.3 million across 5 years, with a median of $13.0 million in 2024.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 101.29% in 2021 and later plummeted 91.2% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $10.5 million in 2021, then soared by 36.19% to $14.3 million in 2022, then decreased by 0.7% to $14.2 million in 2023, then decreased by 4.23% to $13.6 million in 2024, then fell by 8.82% to $12.4 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for ALLO at $12.4 million in Q4 2025, $9.3 million in Q3 2025, and $6.2 million in Q2 2025.